PriceTargets.com logo

NeoGenomics - NEO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.11
  • Forecasted Upside: 7.73%
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$12.17 As of 12/4/2025 05:00 PM ET
▲ +0.05 (0.41%)

This chart shows the closing price for NEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeoGenomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEO

Analyst Price Target is $13.11
▲ +7.73% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $13.11, with a high forecast of $22.00 and a low forecast of $8.00. The average price target represents a 7.73% upside from the last price of $12.17.

This chart shows the closing price for NEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 16 polled investment analysts is to hold stock in NeoGenomics. This rating has held steady since May 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/28/2025Leerink PartnersSet Target$14.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/12/2025CowenReiterated RatingBuy ➝ Buy
9/12/2025TD CowenBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
9/2/2025StephensBoost TargetOverweight ➝ Overweight$6.50 ➝ $11.00
8/29/2025Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $14.00
8/4/2025Piper SandlerSet TargetOverweight ➝ Overweight$12.00 ➝ $11.00
7/30/2025Morgan StanleySet TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00
7/30/2025BTIG ResearchReiterated RatingBuy ➝ Neutral
7/29/2025Needham & Company LLCLower TargetBuy ➝ Buy$8.50 ➝ $8.00
7/29/2025William BlairReiterated RatingOutperform ➝ Market Perform
5/15/2025GuggenheimInitiated CoverageNeutral
5/6/2025Piper SandlerSet TargetOverweight ➝ Overweight$18.00 ➝ $12.00
5/1/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $10.00
4/30/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
4/30/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$15.00 ➝ $10.00
4/30/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$25.00 ➝ $9.00
4/29/2025Needham & Company LLCLower TargetBuy ➝ Buy$18.00 ➝ $8.50
4/17/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$17.00 ➝ $15.00
2/26/2025Piper SandlerLower TargetOverweight ➝ Overweight$21.00 ➝ $18.00
2/19/2025Bank of AmericaLower TargetNeutral ➝ Neutral$19.00 ➝ $16.00
2/19/2025Needham & Company LLCLower TargetBuy ➝ Buy$19.00 ➝ $18.00
1/28/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$20.00 ➝ $18.00
1/13/2025BenchmarkDowngradeBuy ➝ Hold
1/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
12/13/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$18.00 ➝ $19.00
12/10/2024Jefferies Financial GroupInitiated CoverageBuy$22.00
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
9/25/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
9/24/2024BenchmarkReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
7/30/2024StephensReiterated RatingOverweight ➝ Overweight$19.00 ➝ $19.00
7/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
7/30/2024BenchmarkReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
5/2/2024BTIG ResearchLower TargetBuy ➝ Buy$23.00 ➝ $21.00
5/1/2024TD CowenLower TargetBuy ➝ Buy$21.00 ➝ $20.00
5/1/2024BenchmarkReiterated RatingBuy ➝ Buy$18.00
5/1/2024Craig HallumInitiated CoverageBuy$26.00
4/30/2024Needham & Company LLCLower TargetBuy ➝ Buy$24.00 ➝ $19.00
2/26/2024Piper SandlerBoost TargetOverweight ➝ Overweight$18.00 ➝ $20.00
2/22/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$17.00 ➝ $19.00
2/21/2024William BlairReiterated RatingOutperform
2/21/2024Needham & Company LLCBoost TargetBuy ➝ Buy$21.00 ➝ $24.00
12/29/2023TD CowenLower TargetOutperform ➝ Outperform$22.00 ➝ $19.00
12/29/2023BTIG ResearchLower TargetBuy ➝ Buy$25.00 ➝ $21.00
12/28/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$21.00
11/8/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $17.00
11/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$21.00
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$18.00 ➝ $16.00
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$19.00 ➝ $17.00
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$23.00 ➝ $18.00
8/28/2023William BlairReiterated RatingOutperform
8/21/2023StephensUpgradeEqual Weight ➝ Overweight$16.00 ➝ $18.00
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$21.00
8/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$19.00 ➝ $18.00
8/9/2023BenchmarkLower TargetBuy ➝ Buy$20.00 ➝ $18.00
5/16/2023Raymond James FinancialDowngradeOutperform ➝ Market Perform
5/15/2023Piper SandlerBoost Target$20.00 ➝ $23.00
5/9/2023BTIG ResearchUpgradeNeutral ➝ Buy$25.00
4/18/2023Needham & Company LLCReiterated RatingBuy$21.00
4/11/2023Bank of AmericaLower TargetNeutral$18.00 ➝ $17.00
4/5/2023Needham & Company LLCReiterated RatingBuy$21.00
3/3/2023Piper SandlerBoost TargetOverweight$18.00 ➝ $20.00
2/24/2023Needham & Company LLCBoost TargetBuy$15.00 ➝ $21.00
2/24/2023Raymond James FinancialBoost TargetOutperform$12.00 ➝ $19.00
2/24/2023Morgan StanleyBoost TargetEqual Weight$17.00 ➝ $18.00
2/24/2023CowenBoost TargetOutperform$14.00 ➝ $20.00
2/24/2023BenchmarkUpgradeHold ➝ Buy$20.00
2/1/2023Needham & Company LLCUpgradeHold ➝ Buy$15.00
11/15/2022CowenLower Target$17.00
11/14/2022Piper SandlerLower TargetOverweight$19.00 ➝ $18.00
11/11/2022Raymond James FinancialLower TargetOutperform$15.00 ➝ $12.00
11/9/2022Leerink PartnersBoost TargetOutperform$12.00 ➝ $15.00
11/9/2022Morgan StanleyLower TargetEqual Weight$18.00 ➝ $17.00
10/28/2022William BlairReiterated RatingOutperform
8/26/2022BenchmarkDowngradeBuy ➝ Hold
8/22/2022Needham & Company LLCDowngradeBuy ➝ Hold
8/17/2022Piper SandlerBoost TargetOverweight$13.00 ➝ $19.00
8/15/2022CowenBoost Target$18.00
8/15/2022BTIG ResearchDowngradeNeutral
8/10/2022The Goldman Sachs GroupBoost TargetBuy$18.00 ➝ $20.00
8/10/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $18.00
8/10/2022Needham & Company LLCLower TargetBuy$19.00 ➝ $16.00
7/19/2022CowenSet Target$17.00
6/2/2022Piper SandlerInitiated CoverageOverweight$13.00
4/18/2022Raymond James FinancialLower TargetOutperform$24.00 ➝ $18.00
4/12/2022Morgan StanleyLower TargetEqual Weight$29.00 ➝ $27.00
3/29/2022CowenLower TargetOutperform$42.00 ➝ $24.00
3/29/2022BTIG ResearchLower TargetBuy$35.00 ➝ $28.00
3/29/2022BenchmarkLower Target$26.00 ➝ $16.00
3/29/2022Leerink PartnersLower TargetOutperform$45.00 ➝ $20.00
3/29/2022Needham & Company LLCLower TargetBuy$29.00 ➝ $19.00
3/29/2022StephensDowngradeOverweight ➝ Equal Weight$34.00 ➝ $16.00
3/29/2022Bank of AmericaDowngradeBuy ➝ Neutral$25.00 ➝ $18.00
2/24/2022Craig HallumLower Target$46.00 ➝ $30.00
2/24/2022Morgan StanleyLower TargetEqual Weight$30.00 ➝ $29.00
2/24/2022Raymond James FinancialLower TargetOutperform$53.00 ➝ $24.00
2/24/2022Needham & Company LLCLower TargetBuy$41.00 ➝ $29.00
1/12/2022Leerink PartnersLower TargetOutperform$50.00 ➝ $45.00
12/16/2021CowenInitiated CoverageOutperform$42.00
12/7/2021Needham & Company LLCLower TargetBuy$48.00 ➝ $41.00
11/5/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$58.00 ➝ $45.00
11/5/2021StephensLower TargetOverweight$60.00 ➝ $53.00
11/5/2021Needham & Company LLCLower TargetBuy$55.00 ➝ $48.00
11/5/2021Leerink PartnersLower TargetOutperform$63.00 ➝ $60.00
10/14/2021Raymond James FinancialUpgradeMarket Perform ➝ Outperform$53.00
8/26/2021BenchmarkBoost TargetBuy$46.00 ➝ $50.00
8/9/2021Morgan StanleyLower TargetOverweight$64.00 ➝ $58.00
8/9/2021Needham & Company LLCReiterated RatingBuy$55.00
7/13/2021Needham & Company LLCInitiated CoverageBuy$55.00
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$55.00
4/16/2021Needham & Company LLCReiterated RatingBuy$65.00
3/3/2021Raymond James FinancialReiterated RatingOutperform ➝ Market Perform
2/25/2021Craig HallumBoost TargetIn-Line ➝ Buy$50.00 ➝ $65.00
2/25/2021Morgan StanleyBoost TargetOverweight$46.00 ➝ $64.00
2/25/2021Needham & Company LLCInitiated CoverageBuy$65.00
2/25/2021Needham & Company LLCReiterated RatingBuy$65.00
2/25/2021Raymond James FinancialDowngradeOutperform ➝ Market Perform
1/27/2021Truist FinancialInitiated CoverageBuy$65.00
1/8/2021Leerink PartnersBoost TargetOutperform$50.00 ➝ $60.00
12/11/2020BTIG ResearchInitiated CoverageBuy
(Data available from 12/5/2020 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 23 very positive mentions
  • 21 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2025
  • 17 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 4 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 10 very positive mentions
  • 30 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
8/7/2025
  • 18 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 6 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NeoGenomics logo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More

Today's Range

Now: $12.17
Low: $11.94
High: $12.26

50 Day Range

MA: $10.21
Low: $7.72
High: $12.34

52 Week Range

Now: $12.17
Low: $4.72
High: $19.11

Volume

1,233,955 shs

Average Volume

1,981,554 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of NeoGenomics?

The following Wall Street sell-side analysts have issued research reports on NeoGenomics in the last year: Bank of America Corporation, Benchmark Co., BTIG Research, Cowen Inc, Guggenheim, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Piper Sandler, Stephens, TD Cowen, The Goldman Sachs Group, Inc., Wall Street Zen, Weiss Ratings, and William Blair.
View the latest analyst ratings for NEO.

What is the current price target for NeoGenomics?

0 Wall Street analysts have set twelve-month price targets for NeoGenomics in the last year. Their average twelve-month price target is $13.11, suggesting a possible upside of 7.7%. Jefferies Financial Group Inc. has the highest price target set, predicting NEO will reach $22.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $8.00 for NeoGenomics in the next year.
View the latest price targets for NEO.

What is the current consensus analyst rating for NeoGenomics?

NeoGenomics currently has 1 sell rating, 8 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NEO, but not buy more shares or sell existing shares.
View the latest ratings for NEO.

What other companies compete with NeoGenomics?

Other companies that are similar to NeoGenomics include Etsy, StoneCo, Herc, Marathon Digital and WPP. Learn More about companies similar to NeoGenomics.

How do I contact NeoGenomics' investor relations team?

NeoGenomics' physical mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company's listed phone number is (239) 768-0600 and its investor relations email address is [email protected]. The official website for NeoGenomics is www.neogenomics.com. Learn More about contacing NeoGenomics investor relations.